Pfizer (PFE) Non-Current Assets (2009 - 2026)

Pfizer (PFE) has reported Non-Current Assets for 18 consecutive years, with $159.8 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non-Current Assets fell 1.61% year-over-year to $159.8 billion in Q2 2026; TTM through Jun 2026 was $649.4 billion, a 4.38% decrease from a year earlier, with the FY2025 full-year figure at $3.3 billion, up 2.3% from the prior year.
• Non-Current Assets was $159.8 billion for Q2 2026 at Pfizer, down from $165.2 billion in the prior quarter.
• Over five years, Non-Current Assets peaked at $178.7 billion in Q1 2024 and troughed at $3.0 billion in Q4 2023.
• A 5-year average of $110.0 billion and a median of $146.4 billion in 2023 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets fell 15.41% in 2022 and jumped 376.95% in 2024, its largest moves.
• Over 5 years, Non-Current Assets stood at $3.0 billion in 2022, then slipped by 0.17% to $3.0 billion in 2023, then advanced by 7.11% to $3.2 billion in 2024, then rose by 2.3% to $3.3 billion in 2025, then surged by 4746.01% to $159.8 billion in 2026.
• The last three Non-Current Assets figures came in at $159.8 billion (Q2 2026), $165.2 billion (Q1 2026), and $3.3 billion (Q4 2025), per Business Quant data.